Oncologist

Article	Citations
37 Cost-effectiveness of treatment sequences with front-line nivolumab+ipilimumab therapy vs immuno-oncology+tyrosine kinase inhibitor therapies in intermediate/poor-risk metastatic renal cell carcino	179
18 Unraveling the Impact of Tumor Microenvironment on Immunotherapy Response/Resistance in Human Sarcomatoid Clear Cell Renal Cell Carcinoma: Insights from a Novel Mouse Model	115
55 Influence of gender on immunosurveillance in a novel mouse model of clear cell renal cell carcinoma	104
Clinical ethics consultation services: public-facing information on NCI-designated cancer center websites	98
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer	81
Surgical De-Escalation in Medullary Thyroid Cancer: A Commentary	77
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study	65
Correction to: Physician Payments from Pharmaceutical Companies Related to Cancer Drugs	65
The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)	63
Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy	63
46Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC)	56
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis	56
9Characterizing carbonic anhydrase 9 and HIF-2α RNA expression in clear cell renal cell carcinoma (ccRCC)	48
Determining the Cancer Center priorities at the Wilmot Cancer Institute: A proposed framework informed by an academic-community collaborative approach	45
Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience	45
IUC23530-78 Diagnostic value, safety, and patient-reported outcomes of total free-hand LATP biopsy technique	43
Calls to action on lung cancer management and research	43
IUC24430-78 Lesion-level meta-diagnostic of cognitive vs fusion MRI-targeted biopsy in PCa: PRECISION-2 insights	42
IUC24025-78 Early results of moderate hypofractionated radiotherapy implementation for localized prostate cancer patients in Vietnam	41
GBAS Regulates the Proliferation and Metastasis of Ovarian Cancer Cells by Combining with eEF1A1	40
Palliative Rehabilitation in Acute Inpatient Rehabilitation: Prognostic Factors and Functional Outcomes in Patients with Cancer	40
Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer	40
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy	38
Contextualizing results of randomized trials in smoldering myeloma	36
A blueprint for creating an early-onset colorectal cancer program based on experiences from seven clinical centers across the United States and Canada	36

ALK-positive adult histiocytosis with a TFG-ALKfusion gene	36
Neoadjuvant rectal-tumor regression grade combined score as surrogate endpoint for disease-free survival in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy	35
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay	35
Correction to: Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)	35
Implementation of neoadjuvant immunotherapy in stage III melanoma: a modified Delphi consensus study in a European-accredited cancer center in Ireland	35
Classification of NK-large granular lymphocytic leukemia by CD56 expression	35
“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management	34
Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation	34
8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial	34
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer	34
Exploring immune activation patterns in HER2-low and HER2-ultralow breast cancer subtypes	34
Large language model processing capabilities of ChatGPT 4.0 to generate molecular tumor board recommendations—a critical evaluation on real world data	33
Patients’ and caregivers’ perspectives on preparedness for and experience with chimeric antigen receptor T-cell therapy	33
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data	33
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis	32
Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles	32
Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma	31
The Use of Natural Language Processing to Assess Social Support in Patients With Advanced Cancer	31
First-in-human phase I open-label study of the anti–TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors	31
Prevalence ofBRCA1andBRCA2Germline Mutations in Patients of African Descent with Early-Onset and Familial Colombian Breast Cancer	31
Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities	30
First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity	29
Evaluating the Effectiveness of Mobile Health in Breast Cancer Care: A Systematic Review	29
Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience	29
Antibody drugs conjugates in non–small cell lung cancer: current status and challenges	28
Rural-Urban Disparities in Colorectal Cancer Screening, Diagnosis, Treatment, and Survivorship Care: A Systematic Review and Meta-Analysis	28
Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events	28
56 Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship Confirms Best-in-class Potential of Casdatifan (AB521), a Small Molecule Inhibitor of HIF-2α Being Developed in Renal Cancer	28
Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate	28
Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results	28
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma	27
Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up	27
It is time to rethink randomized clinical trial approaches	27
The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research	27
74 Unraveling the Complexities of Obesity in Clear Cell Renal Cell Carcinoma Carcinogenesis	27
Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy	27
A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment	27
Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget’s disease	27
Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy	27
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study	27
Assessing the clinical readiness of the SERENA-6 strategy	27
Characteristics and availability of medicine early access programs and donations in Slovenia	26
Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study	26
Evaluation of a risk-sharing agreement for atezolizumab treatment in patients with non-small cell lung cancer: a strategy to improve access in low-income countries	26
An early relapse prediction model based on pathological features following neoadjuvant immunotherapy for hepatocellular carcinoma	26
IUC24420-77 Prognostic impact of ABCA1/ABCG1 expression, lipid parameters, and nephrectomy in patients with renal cell carcinoma receiving immune checkpoint inhibitors	25
Systemic inflammation and changes in physical well-being in patients with breast cancer: a longitudinal study in community oncology settings	25
IUC24411-77 In search of metastasis-initiating cells in prostate cancer	25
Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC	25
Oncofusions – shaping cancer care	24

Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer	24
Days spent with healthcare contact by patients with metastatic castrate resistant prostate cancer in the last year of life	24
4CD163+ Tumor-Associated macrophages and clinical outcomes to First-Line nivolumab therapy in patients with metastatic clear cel renal cell carcinoma: insights from the HCRN GU16-260 trial	24
Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board	24
35FGD1 splice variant as a novel biomarker for inferior clinical outcomes and development of brain and bone metastasis in clear cell renal cell carcinoma	24
SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma	23
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy	23
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors	23
Inequity in Telemedicine Use Among Patients with Cancer in the Deep South During the COVID-19 Pandemic	23
Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer	23
Prevalence and associated factors of persistent precancerous lesions among women treated for cervical lesions in Addis Ababa, Ethiopia	23
Understanding variants of unknown significance and classification of genomic alterations	23
Palliative Care Interventions and End-of-Life Care for Patients with Metastatic Breast Cancer: A Multicentre Analysis	23
Deep Learning of Multimodal Ultrasound: Stratifying the Response to Neoadjuvant Chemotherapy in Breast Cancer Before Treatment	23
Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma	22
Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan	22
First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape	22
Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness	22
Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis	22
25 Enrichment of tertiary lymphoid structures provides novel insight into mediators of anti-tumor immune activity in sarcomatoid renal cell carcinoma	22
Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States	21
The association of health care contact days with economic measures in the CCTG LY.12 trial	21
Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials	21
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma	21
Proceedings of the 1st biannual bridging the gaps in lung cancer conference	21
Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis	21
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study	21
Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma	20
HER2 alterations across solid tumors: implications for comprehensive testing	20
Clinical response to novel combination of trastuzumab deruxtecan and abiraterone in HER2-expressing metastatic castration-resistant prostate cancer	20
Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?	20
Stepping Down, Looking Forward	20
Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?	20
Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study	20
Synchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series	20
IUC23223-77 Triplet therapy in metastatic hormone-sensitive prostate cancer in Asian patients	20
IUC24392-85 Real-world use of erdafitinib in urothelial carcinoma: an Italian multicenter retrospective study	19
Risk of myelodysplastic syndrome and acute myeloid leukemia related to PARP inhibitor maintenance line in real-world ovarian cancer patients	19
7Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA)	19
68Targeting the BBOX1-TBK1-mTORC1 axis in clear cell renal cell carcinoma	19
50Clinical characteristics, determinants and subsequent therapy of primary refractory metastatic renal cell carcinoma (mRCC): an international metastatic database consortium (IMDC) study	19
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399	19
58Dissecting the interplay between Bap1 and Pbrm1 in renal cell carcinoma	19
33fusion derived oncogenic programs shape the immune landscape in translocation renal cell carcinoma	19
IUC24394-87 Meet-URO score update in metastatic renal cell carcinoma receiving first-line immune-combinations	19
Chatbot assistance in precision oncology treatment decision-making	19
IUC24405-80 Retrospective study of apalutamide/enzalutamide in hormone-sensitive metastatic prostate cancer	19
Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitors	19
Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities	18
Impact of Primary Breast Surgery on Overall Survival of Patients With De Novo Metastatic Breast Cancer: A Systematic Review and Meta-Analysis	18
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab	18
Advances in the management of patients with idh-mutant glioma	18
Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53	18
Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review	18
Machine learning models for predicting postoperative peritoneal metastasis after hepatocellular carcinoma rupture: a multicenter cohort study in China	18
Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit	18
Long-Term Risk of Subsequent Malignant Neoplasms Among Childhood and Adolescent Lymphoma Survivors (1975-2013): A Population-Based Predictive Nomogram	18
Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer	18
Immune-related encephalitis after immune checkpoint inhibitor therapy	18
Ovarian clear cell carcinoma: open questions on the management and treatment algorithm	18
Effects of a 12-Week Multimodal Exercise Intervention Among Older Patients with Advanced Cancer: Results from a Randomized Controlled Trial	18
KRASMutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas	17
Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression	17
Medical accuracy of artificial intelligence chatbots in oncology: a scoping review	17
Is it time to retire preoperative radiation for localized esophageal and gastro-esophageal adenocarcinoma?	17
The Impact of Breast Cancer Treatment Delays on Survival Among South African Women	17
First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study	17
A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma	17
Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer	17
A mixed-method analysis of oncologist-patient communications about immune checkpoint inhibitors (COACH)	17
Correction to: Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake	17
Opioid use and adverse health effects in breast cancer survivors	17
Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer patients: demystifying the 100% clinical complete response paradigm	17
Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice	17
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors	17
COVID-19 burden of illness in people who are immunocompromised due to cancer: an expert opinion review	16
Symptom Clusters in Patients With Advanced Cancer: A Prospective Longitudinal Cohort Study to Examine Their Stability and Prognostic Significance	16
Advances and future directions in ROS1 fusion-positive lung cancer	16
A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX	16
Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan	16

First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer	16
Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial	16
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer	16
A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors	16
Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patients	16
Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases	16
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab	16
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast	16
Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma	16
Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma	15
Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments	15
Emerging treatment modalities for gastric cancer with peritoneal metastases: a systematic review	15
IUC24412-78 The safety and efficacy of a modified Di stasi regime for patients with non-muscle invasive bladder cancer during times of bacillus Calmette-Guérin shortage	15
Real-world effectiveness of mitoxantrone hydrochloride liposome containing regimens in acute myeloid leukemia	15
Stigma and Social Determinants of Health Associated With Fidelity to Guideline-Concordant Therapy in Patients With Breast Cancer Living With and Without HIV in Botswana	15
Duration of Chemotherapy-induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles	15
Outcomes of palliative porto-mesenteric venous stenting in unresectable pancreatic malignancies	15
The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms	15
STARLITE 1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC	15
Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment: A Systematic Review	15
18F-FDG PET/CT for early prediction of pathological complete response in breast cancer neoadjuvant therapy: a retrospective analysis	15
ORCHID: A phase II study of Olaparib in Metastatic Renal Cell Carcinoma Patients HarborIng a BAP1 or Other DNA Repair Gene Mutations	15
An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer	15
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study	15
Clinicopathological characteristics of progressive gastrointestinal stromal tumors and heterogeneity analyses of secondary mutations	15
Benign Metastasizing Leiomyomatosis to the Skin and Lungs, Intravenous Leiomyomatosis, and Leiomyomatosis Peritonealis Disseminata: A Series of Five Cases	15
Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors	15
Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study	15
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel	14
A Lung Cancer Patient’s Passionate Desire for Sexual Healing	14
Adjuvant transarterial chemoembolization plus lenvatinib for patients with HCC with MVI after resection: a multicenter retrospective study	14
Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies	14
Availability of Results of Trials Studying Pancreatic Adenocarcinoma over the Past 10 Years	14
Intravenous haloperidol or chlorpromazine—which is more effective to improve agitation and communication in agitated delirium at the end of life?	14
The utility of ctDNA in rectal cancer	14
Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors	14
Correction to: A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study	14
Correction to: Comparing Drug Shortages Experienced by Institutions With National Metrics	14
A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy	14
Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE	14
Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101	14
Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer	14
Early follow-up of outpatients with oral anticancer therapy in the ONCORAL multidisciplinary community-hospital program	14
Spatial proteomics enables identification of prognostic biomarkers in papillary renal cell carcinoma	14
54 MicroRNA Signatures in Clear Cell Renal Cell Carcinoma: Exploring Potential Implications for Prognosis	14
Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia	14
Physical Function, Psychosocial Status, and Symptom Burden Among Adults with Plasma Cell Disorders and Associations with Quality of Life	14
Adjuvant treatment preferences in high-risk upper tract urothelial carcinoma: the perspective of Portuguese medical oncologists	14
Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK	14
Implementation of Precision Oncology in Clinical Practice: Results of a National Survey for Health Care Professionals	14
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer	13
IUC24409-84 Evaluation of a transurethral laser ablation (TULA) service for superficial bladder cancer management in an outpatient setting in a UK district general hospital	13
Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial	13
Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial	13
Cardiotoxicity from Capecitabine Chemotherapy: Prospective Study of Incidence at Rest and During Physical Exercise	13
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan	13
Efficacy and safety of pyrotinib in patients with previously treated HER2-positive non-breast solid tumors: a phase 2, open-label basket trial	13
The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice	13
IUC24428-85 Real-world effectiveness of ipilimumab plus nivolumab in second-line in patients with metastatic clear cell renal cell carcinoma (mccRCC) based on prior receipt of PD-1/L1 inhibitors	13
The cancer caregiving burden trajectory over time: varying experiences of perceived versus objectively measured burden	13
Supporting patients with advanced cancer and their spouses in parenting minor children: results of a randomized controlled trial	13
Researcher Experience and Comfort With Telemedicine and Remote Patient Monitoring in Cancer Treatment Trials	13
A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors	13
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study	13
Validation of the FACIT-Fatigue scale in patients with locally advanced or metastatic breast cancer	13
Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab	13
Trends, Changes, and Disruptions: The Fragile Economics of Cancer Treatments	13
Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents	13
Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies	12
Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications	12
Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma	12
Comparisons of Non-Oral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles	12
Correction to: Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma	12
Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes	12
Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US	12
Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution	12
Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic	12
Perioperative therapy for limited-stage small cell esophageal carcinoma: a retrospective cohort study	12
Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer	12
PARP inhibitors in gastric cancer: unlocking precision oncology	12
Coping and Perception of Prognosis in Patients With Indolent Non-Hodgkin’s Lymphoma	12
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer	12
From ownership to custodianship of tumor biopsy tissue in genomic testing: a mixed methods study of patient views	12
Therapeutic targeting of the protein tyrosine kinase-7 in cancer: an overview	12
Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analyses	12
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers	12
14 Natural killer cells have impaired cytotoxicity in advanced renal cell carcinoma	12
LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma	12
Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational study	12
Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma	12
Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma	12
Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment	12
Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center	12
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation	12
Combination therapy for platinum-resistant ovarian cancer: a novel at-home regimen with envafolimab, lenvatinib, and etoposide	12